AMERANT BANK NAMED TO THE 2025 AMERICA’S TOP 100 MOST LOVED WORKPLACES® LIST Amerant Bank Ranked as #29 Among Top 100 U.S. Companies, Up Twelve Spots from 2024 Coral Gables, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Most Loved Workplace® has released the 2025 America’s Top 100 Most Loved Workplaces®. The rankings, published today in the , highlight 100 organizations across industries that are transforming employee experience and redefining workplace culture. Amerant Bank was ranked #29 on this prestigious list, moving up 12 spots from 2024 and making this the fourth consecutive year the Ban...
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral presentation at American College of Rheumatology (ACR) Convergence 2025 in Chicago, IL, Oct. 24 – 29...
AMERANT BANK, SEDANO’S, AND FRESCO Y MÁS PRESENT DONATION TO CENTRO MATER FOLLOWING SUCCESSFUL COMMUNITY CAMPAIGN Reusable Bag Program at Sedano’s and Fresco y Más Locations Helped Raise Funds to Support Educational and Social Services for Local Families Miami, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Florida’s bank of choice, in partnership with Sedano’s Supermarkets, one of Florida's leading supermarket chains serving Hispanic communities, proudly announced the final donation to Centro Mater, a prominent local children’s charity, following the successful conclusion of their community-d...
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innov...
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14. The event will include Joseph A. Murray, M.D., professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology at ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.